To test whether application of topical heparin solution around the IV cannula site daily would reduce the occurrence of superficial inflammation of veins when compared to a placebo
Phase 3
- Conditions
- Health Condition 1: I809- Phlebitis and thrombophlebitis ofunspecified site
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Children aged 1 month-14 years admitted in inpatient department requiring IV cannulation for at least 72 hours
2.Parents who have given written informed consent
Exclusion Criteria
Children who required iv access in the last 28 days, have hypersensitivity to heparin, have any condition which has procoagulant tendency, already on anticoagulant therapy or planned for anti coagulant therapy, already on non-steroidal anti-inflammataory drugs or planned for non-steroidal anti-inflammataory drugs
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The difference in proportion of children who have no phlebitis between the children who receive topical heparin quick penetrating solution and a topical placeboTimepoint: 72 hours
- Secondary Outcome Measures
Name Time Method The difference in proportion of children who develop grade 1 or grade 2 phlebitis between the children who receive topical heparin quick penetrating solution and a topical placeboTimepoint: 72 hours;The mean difference of time in hours to develop grade 1 or grade 2 between the children who receive topical heparin quick penetrating solution and a topical placeboTimepoint: 72 hours